8% Off
Ifomes400 mg/4 m
Beacon Pharmaceuticals PLC
৳174.80
Add to cart
Generic medicine
Mesna: Brands, Price & Uses in Bangladesh
Mesna is an FDA-approved uroprotective (cytoprotective) agent indicated specifically for: Prophylaxis of ifosfamide-induced hemorrhagic cystitis - established, on-label use.
About Mesna
Indications of Mesna
Mesna is an FDA-approved uroprotective (cytoprotective) agent indicated specifically for:
- Prophylaxis of ifosfamide-induced hemorrhagic cystitis - established, on-label use. Mesna is given together with ifosfamide chemotherapy to reduce the incidence and severity of hemorrhagic cystitis.
- Prophylaxis of hemorrhagic cystitis induced by high-dose cyclophosphamide (e.g., in conditioning regimens prior to stem cell/bone marrow transplantation) - a guideline-supported, widely used practice, including some off-label/protocol-based dosing in this setting.
Mesna is not indicated to reduce hematuria from other causes (such as thrombocytopenia or tumor invasion of the bladder) and does not treat or prevent any other toxicity of ifosfamide or cyclophosphamide, including myelosuppression or antitumor-unrelated adverse effects. Mesna does not reduce the antitumor efficacy of ifosfamide or cyclophosphamide.
Dosage & Administration of Mesna
Mesna dosing is calculated as a percentage of the ifosfamide or cyclophosphamide dose (by body surface area) and must be given on a strict schedule relative to the chemotherapy infusion. Exact regimens vary by protocol; the following reflects commonly used, label-based schedules for adults.
| Regimen | Mesna dose/timing |
|---|---|
| IV bolus regimen (with ifosfamide) | Mesna 20% of the ifosfamide dose given IV at the time of ifosfamide administration (hour 0), then repeated at 4 and 8 hours after each ifosfamide dose (total Mesna dose = 60% of ifosfamide dose per cycle day). |
| IV + oral regimen (with ifosfamide) | Mesna 20% of ifosfamide dose IV at hour 0, then 40% of the ifosfamide dose given orally at 2 and 6 hours after each ifosfamide dose (total Mesna dose = 100% of ifosfamide dose). |
| High-dose cyclophosphamide (transplant conditioning) | Continuous infusion or intermittent bolus dosing of Mesna, typically 60-160% of the cyclophosphamide dose in divided doses, per institutional/transplant protocol. |
Administration: Mesna IV injection should be diluted in compatible IV fluids (e.g., 5% dextrose, normal saline, or Ringer's lactate) to a final concentration around 20 mg/mL and used within 24 hours of dilution. It can be given as a slow IV bolus or short infusion. Oral Mesna tablets should be taken with a liquid, with or without food; if vomiting occurs within 2 hours of an oral dose, the dose should be repeated or switched to the IV route, as directed by the treating physician.
Maintain generous fluid intake/hydration before, during, and after chemotherapy, and monitor urine for blood (hematuria) with each cycle, even when Mesna is given as prescribed. Always follow the exact dose, route, and schedule prescribed by the oncology team; do not adjust Mesna timing independently, as inadequate Mesna dosing or mistimed doses increase the risk of hemorrhagic cystitis. See Use in Special Populations for renal impairment considerations.
Side Effects of Mesna
Adverse effects reported with Mesna can be difficult to distinguish from those of the concurrent ifosfamide/cyclophosphamide chemotherapy, but commonly reported reactions (more than 10% of patients) include:
- Nausea and vomiting
- Diarrhea and constipation
- Fatigue, fever, and loss of appetite (anorexia)
- Headache
- Low blood counts (leukopenia, thrombocytopenia, anemia) - largely attributable to the co-administered chemotherapy
Less common but important reactions include allergic-type hypersensitivity reactions (rash, urticaria, pruritus, flushing, and rarely anaphylaxis), and rare severe skin reactions (Stevens-Johnson syndrome/toxic epidermal necrolysis) have been reported. Seek prompt medical attention for any rash, swelling of the face/lips/tongue, difficulty breathing, or skin blistering during Mesna therapy.
Contraindications of Mesna
Mesna is contraindicated in patients with known hypersensitivity to Mesna or to other thiol (sulfhydryl) compounds. There are no other well-established absolute contraindications to Mesna itself; other cautions (e.g., benzyl alcohol content in some formulations) are addressed under Precautions and Warnings and Use in Special Populations rather than as absolute contraindications.
Frequently Asked Questions about Mesna
What is Mesna used for?
Mesna is used to help prevent hemorrhagic cystitis (bladder irritation and bleeding) caused by certain chemotherapy drugs, specifically ifosfamide and high-dose cyclophosphamide. Mesna does not treat cancer itself and is always given together with, not instead of, chemotherapy.
Does Mesna reduce how well my chemotherapy works?
No. Mesna only neutralizes a toxic byproduct in the urinary tract and does not reduce the antitumor effectiveness of ifosfamide or cyclophosphamide, nor does it protect against their other side effects such as low blood counts or nausea.
Why is the timing of Mesna doses so important?
Mesna only protects the bladder while it is present in the urine at adequate concentrations. If doses of Mesna are missed, delayed, or reduced, the risk of hemorrhagic cystitis increases significantly, so it is essential to take or receive every dose of Mesna exactly on the schedule your oncology team prescribes.
What side effects should I watch for with Mesna?
Common side effects of Mesna include nausea, vomiting, diarrhea, fatigue, and mild allergic-type reactions such as rash. Seek immediate medical attention for signs of a severe allergic reaction (facial or throat swelling, difficulty breathing) or severe skin blistering/peeling, as these are rare but serious reactions that have been reported with Mesna.
Can Mesna be used during pregnancy or breastfeeding?
Mesna is given together with chemotherapy drugs that can harm a developing fetus, so it should be used in pregnancy only if your oncology team determines the benefit outweighs the risk, under close specialist supervision. Breastfeeding should be avoided during treatment with Mesna and for at least one week after the last dose; ask your physician before resuming breastfeeding.
What should I do if I miss a dose or vomit after an oral Mesna tablet?
If you vomit within about 2 hours of taking an oral Mesna dose, or think you have missed a dose, contact your oncology team immediately rather than deciding on your own - the missed dose may need to be repeated or given by the intravenous route to maintain protection against hemorrhagic cystitis.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.